Natalie Stratton

发表

PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.

Nicholas J. Slipek, D. Largaespada, B. Moriarity, 2020, Bone.

Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma

Nicholas J. Slipek, D. Largaespada, B. Moriarity, 2020, Molecular Cancer Therapeutics.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

C. A. Roberts, A. Rabow, M. Waring, 2016, Journal of medicinal chemistry.

Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer

A. Rabow, C. Robson, G. Walker, 2012 .

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Rhys D O Jones, A. Rabow, S. Barry, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics AZD 3514 : A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Rhys D O Jones, A. Rabow, S. Barry, 2013 .

Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.

Rhys D O Jones, A. Rabow, G. Walker, 2013, Bioorganic & medicinal chemistry letters.

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.

B. Barlaam, P. Macfaul, S. Pearson, 2018, ACS medicinal chemistry letters.

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).

Nichola L. Davies, B. Barlaam, S. Degorce, 2018, Journal of medicinal chemistry.

Potent and selective bivalent inhibitors of BET bromodomains.

A. Dulak, A. Rabow, M. Waring, 2016, Nature chemical biology.